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ABSTRACT 
Systematic phytochemical investigations of the underground rhizome of Pteridium aquilinum 
(L.) Kuhn (Dennstaedtiaceae) afforded thirty-five pterosins and pterosides. By detailed analysis 
of one- and two-dimensional nuclear magnetic resonance spectroscopy, circular dichroism (CD) 
and high-resolution mass spectrometric data, thirteen previously undescribed pterosins and 
pterosides have been identified. Interestingly, for the first time 12-O-β-D-glucopyranoside 
substituted pterosins, rhedynosides C and D, and the sulfate-containing pterosin, rhedynosin H, 
alongside the two known compounds, histiopterosin A and (2S)-pteroside A2, were isolated from 
the rhizomes of subsp. aquilinum of bracken. In addition, six-membered cyclic ether pterosins 
and pterosides, rhedynosin A and rhedynoside A, are the first examples of this type of pterosin-
sesquiterpenoid. Additionally, the three previously reported compounds (rhedynosin I, (2S)-2-
hydroxymethylpterosin E and (2S)-12-hydroxypterosin A) were obtained for the first time from 
plants as opposed to mammalian metabolic products. Single crystal X-ray diffraction analysis 
was applied to the previously undescribed compounds (2R)-rhedynoside B, (2R)-pteroside B and 
(2S)-pteroside K, yielding the first crystal structures for pterosides, and three known pterosins, 
(2S)-pterosin A, trans-pterosin C and cis-pterosin C. Rhedynosin C is the only example of the 
cyclic lactone pterosins with a keto group at position C-14. Six selected pterosins ((2S)-pterosin 
A, (2R)-pterosin B and trans-pterosin C) and associated glycosides ((2S)-pteroside A, (2R)-
pteroside B and pteroside Z) were assessed for their anti-diabetic activity using an intestinal 
glucose uptake assay; all were found to be inactive at 300 µM. 
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1. Introduction 
One of the most widely distributed vascular plant species in the world is bracken (Pteridium 
aquilinum (L.) Kuhn). In the UK, P. aquilinum subsp. aquilinum comprises the majority of 
bracken, with a dense coverage estimated at 4782 km2 (dense) or 17000 km2 (presence), 
representing 7% of the land area in the UK, including sparse bracken (Pakeman et al., 1996). This 
corresponds to 1.1 - 5 Gigatonne (Gt) of plant material above ground and 5 - 20 Gt of rhizome 
biomass (dry weight, calculated from data in (Marrs and Watt, 2006)). Bracken has long been 
recognised for its potential pharmaceutical uses and its toxicity. Furthermore, bracken has been 
used medicinally as an anthelminthic agent (Marrs and Watt, 2006). Bracken crosiers have been 
eaten as a delicacy in Japan and Brazil. The rhizome has been used as a source of starch (Alonso-
Amelot and Avendano, 2002; Madeja et al., 2009). 
Phytochemical studies of bracken are most often concerned with the norsesquiterpene glycoside 
ptaquiloside, because of its established carcinogenicity (Fenwick, 1988; Hirono, 1986). Research 
has been concentrated on the quantification of this compound in the plant (Alonso-Amelot et al., 
1992; Rasmussen et al., 2003) and in biological samples, such as urine, milk and plasma (Aranha 
et al., 2014). Ptaquiloside is unstable due to the presence of a spirocyclopropane moiety. The main 
degradation product of ptaquiloside is pterosin B (Hirono, 1986). Other pterosins have been 
isolated from different subsp. of Pteridium aquilinum (Fukuoka et al., 1978; Kuraishi et al., 1985; 
Murakami et al., 1980; Sengupta et al., 1976; Tanaka et al., 1982; Yoshihira et al., 1971). Pterosins 
are sesquiterpenoids and their structures are derivatives of 1-indanone. They are biosynthesised in 
all parts of the bracken, including fronds and rhizomes (Hikino et al., 1976; Kigoshi et al., 1989). 
Bracken has historically been associated with incidents of livestock poisoning (Hopkins, 1990; 
Vetter, 2009) resulting in many mechanistic studies on distinct pterosins and their biological 
targets. For example, pterosin B was found to inhibit the Gram-positive bacterium Bacillus subtilis 
at minimum inhibitory concentration (MIC) of 30 µg ml-1 (Kobayashi et al., 1975). Pterosins B, 
F, H, I, O, Z and V showed cytotoxic effects on Paramecium caudatum and caused abnormal 
development of sea urchin embryos but did not inhibit DNA synthesis (Kobayashi and Koshimizu, 
1980). Pterosin Z is a potent relaxant to smooth muscle (EC50 = 1.3 ± 0.1 µM) (Sheridan et al., 
1999). In addition, the interaction of bracken extract with vitamin C in human submandibular and 
oral epithelial cell lines has been assessed (Campos-da-Paz et al., 2008) and the dependency of 
the biological effect of bracken extract in different cell assays has been evaluated (Almeida Santos 
et al., 2006). Anti-diabetic activity has also been associated with pterosins (Hsu et al., 2014), and 
studies using distinct pterosins, methanolic extracts of bracken have been used to investigate 
glycophenotypic alterations in mice gastric mucosa (Gomes et al., 2012). 
The toxicity of North Wales bracken, ‘Rhedyn’ in the Welsh language, to cattle has been studied 
previously (Potter, D.M., Baird, 2000; Yamada et al., 2007). Recently, a traditional phytochemical 
investigation of bracken rhizomes using various analytical techniques led to the isolation of 
thirteen novel compounds (1-13) (Figs. 1 & 2), together with twenty two known compounds: 
rhedynosin I (14), (2S)-pterosin A (15), (2R)-pterosin B (16), (2R, 3R)-pterosin C (trans-pterosin 
C) (17), (2S, 3R)-pterosin C (cis-pterosin C) (18), (3S)-pterosin D (19), (2R)-pterosin E (20), (2R)-
pterosin F (21), (2S, 3S)-pterosin J (22), (2S)-pterosin K (23), (2S)-pterosin N (24), (2S)-pterosin 
P (25), pterosin Z (26), (2S)-2-hydroxymethylpterosin E (27), histiopterosin A (28), (2S)-12-
hydroxypterosin A (29), (2S)-pteroside A (30), (2R)-pteroside B (31), (3S)-pteroside D (32), 
pteroside Z (33), (2S)-pteroside A2 (34) and (2S)-pteroside K (35), of which compounds 14 and 
27-29 are identified for the first time from the genus Pteridium which belongs to Dennstaedtiaceae 
family (Figs. 1-3). Herein described are the isolation and structural elucidation of these 
compounds. 
 
2. Results and Discussion: 
The underground parts (rhizomes) of bracken (Pteridium aquilinum (L.) Kuhn) were air-dried, 
chopped and then extracted with chloroform. More than twenty sesquiterpenoid constituents have 
been identified with UV absorption spectra profiles in the 340 to 205 nm region characteristic of 
1-indanone derivatives (Fukuoka et al., 1978; Kuraishi et al., 1985; Murakami et al., 1980; 
Yoshihira et al., 1971). The chloroform extract was repeatedly subjected to thin-layer, normal-
phase column, and automated reversed phase flash chromatography to afford thirty five 
compounds (1-35). One- and two-dimensional NMR experiments combined with mass 
spectrometry were used to identify thirteen novel natural products (1-13) (Supplementary 
Information 1) belonging to the sesquiterpenoid family. The structures of twenty two previously 
reported pterosins and pterosides 14, 27, 29 (Lee et al., 2012), 15-18, 30-33, 35 (Kuroyanagi et 
al., 1979), 19-25 (Fukuoka et al., 1978), 26 (Kuraishi et al., 1985; Tanaka et al., 1982), 28 
(Murakami et al., 1980), 34 (Castillo et al., 2003) were determined by the comparison of their 
spectroscopic data with those reported in the literature (Figs. 1-3). The structures of compound 1-
13 are shown in Figs. 1 & 2 and their 1H and 13C data is listed in Tables 1-4.  
X-ray crystallography remains the definitive tool to determine the absolute configuration but 
requires the existence of good crystals. Circular Dichroism (CD) is a technique that can be used 
to assign the absolute configuration in solution with less than 1 mg of compound (Warnke and 
Furche, 2012). However, CD is only reliable for the determination of absolute configuration if 
chromophores are in close spatial proximity allowing for exciton coupling. Unfortunately, this is 
not the case with the compounds discussed here. In the past, sector rules (eg octant rules) were 
invoked in order to assign the absolute configuration of compounds composed of a chromophore 
in a dissymmetric environment. However, such rules are now considered with scepticism.  
Nevertheless, careful pair-wise comparison of the CD of compounds with identical chromophore 
cores (Fig. 4) and similar dissymmetric environments enables correlation. Unfortunately, the large 
perturbing influence of a glycosyl-residue in the structure can hamper comparison with glucose-
free compounds. 
The UV and CD spectra in the 380 nm to 260 nm region associated with the keto group 
 n → π* transition can be deceptively complex. The electron transitions primarily observed in an 
UV spectrum produce fairly straightforward spectral data. However, the presence of vibronic 
effects (coincidental change of vibrational and electronic energy levels) may add complexity to 
the signal, e.g., in form of additional shoulders. The corresponding CD spectra obey different 
selection rules. The CD associated with the n → π* transition may mimic the absorption spectrum 
and be relatively plain or may be fine structured indicating the importance of particular vibronic 
progressions. In the series outlined here, compound 1, 14, 15, 23, 27, 29 and 30 present CDs with 
vibronic fine structure, while compounds 2, 7, 34, 35 render relatively featureless spectra. 
Comparison of the CD spectra with X-ray data or published CD data (Kuroyanagi et al, 1979) 
revealed that the stereogenic centre in the core aglycone (Fig. 4) of all compounds 1, 2, 7, 14, 15, 
23, 27, 29, 30, 34, 35 can be assigned as 2S.  
 
2.1. Structural Elucidation 
Compound 1 was obtained as a yellow powder and its molecular formula was established as 
C15H18O3 based on the positive mode quasi-molecular ion peak at m/z 247.1330 [M+H]
+ (calcd for 
C15H19O3, 247.1334) showing 7 degrees of unsaturation. The UV absorbance maxima at 211, 258 
and 306 nm were consistent with 1-indanone derivatives. The IR absorption bands at 3014, 1605, 
3418 and 1704 cm-1 indicated the presence of aromatic C-H, C=C, hydroxyl and carbonyl groups, 
respectively, which concur with the presence of a 1-indanone skeleton (Fukuoka et al., 1978; 
Kuroyanagi et al., 1979). 
The full assignment of 1H and 13C NMR resonances was deduced from 1H-1H COSY, DEPTQ, 
HSQC and HMBC analysis (Tables 1 & 4, Fig. 5 and Supplementary Information 1). The signals 
for all protonated carbons were assigned by analysis of the DEPTQ and HSQC spectra to establish 
the connectivity. The 1H NMR spectrum of 1 shows signals of one secondary methyl [(3H, 
s, H-15)], one tertiary methyl [ 1.23 (3H, s, H-10)], two methylenes [ 2.77, 3.06 (2H, d, J = 
17.5 Hz, H-3) and 2.76 (2H, t, J = 5.9 Hz, H-13)], three oxygenated methylenes [ 3.62, 3.78 
(2H, d, J = 10.8 Hz, H-11), 4.80 (2H, s, H-12) and 4.01 (2H, td, J = 1.3, 5.9, 11.8 Hz, H-14)] and 
one methine [ 6.93 (1H, s, H-4)] signal in the aromatic region. The DEPTQ spectrum, in 
combination with HSQC and HMBC data, displays 15 carbon resonances, including two 
quaternary methyls at C 21.1 (C-10) and C 13.1 (C-15), five methylenes (including three 
oxygenated carbons), one methine at C 120.0 (C-4) and seven quaternary carbons. As three of the 
7 degrees of unsaturation are accounted for by a tricyclic system of 1, the remaining 4 degrees of 
unsaturation require 4 double bonds. The key HMBC correlations are shown in Fig. 5. In the 
HMBC spectrum, the signals at δH 2.77 and 3.06 (2H, d, J = 17.5 Hz, H-3) shows correlations 
with δC 50.9 (C-2), δC 138.2 (C-7), δC 131.3 (C-8), δC 151.0 (C-9), δC 21.1 (C-10) and δC 68.3 (C-
11). δH 4.80 (2H, s, H-12) displays correlations with δC 120.0 (C-4), δC 142.1 (C-5), δC 131.8 (C-
6) and δC 65.6 (C-14). δH 2.76 (2H, t, J = 5.9 Hz, H-13) exhibits correlations with δC 142.1 (C-5), 
δC 131.8 (C-6) and δC 138.2 (C-7). δH 4.01 (2H, td, J = 1.3, 5.9, 11.8 Hz, H-14) reveals correlations 
with δC 131.8 (C-6), 68.8 (C-12) and δC 25.8 (C-13). δH 3.62, 3.78 (2H, d, J = 10.8 Hz, H-11) is 
correlated with δC 210.5 (C-1), δC 50.9 (C-2), δC 37.1 (C-3) and δC 21.1 (C-10). The latter 
correlations confirmed the position of the hydroxymethylene (CH2OH) group at C-2. Other 
connectivities shown in this spectrum are: δH 6.93 (1H, s, H-4) with C-3, C-6 & C-12, δH 1.23 
(3H, s, H-10) with C-1, C-2, C-3 & C-11 and δH 2.56 (3H, s, H-15) with C-6, C-7 & C-8. The 
presence of an ether link was assigned to be between positions C-12 and C-14 as their proton and 
carbon chemical shifts appeared at the low field region due to the deshielding influence of the 
oxygen atom. This was further confirmed with the HMBC spectrum that showed the correlations 
from H-12 ( 4.80) to C-14 (C 65.6) and from H-14 ( to C-12 (C 68.8). The J-coupling 
systems were confirmed by COSY data that displays couplings between signals: δH 2.76 & δH 4.01, 
δH 2.77 & δH 3.06, and δH 3.62 & δH 3.78, respectively. 
The CD spectrum of 1 shows a vibronic n → π* transition (Fig. 6) which concurs with C-2 having 
2S configuration. The observed transitions for the assignment of the absolute stereochemistry were 
based on the comparison of CD spectra of 1 with X-ray crystallography data of 15 (Fig. 7) and the 
CD interpretation provided for 15 by Kuroyanagi et al., 1979. Based on the above analysis, the 
structure of this compound was determined as a new natural product and named rhedynosin A (1). 
Its physical and spectroscopic features were consistent with the proposed structure in Fig. 1.  
Compound 2 was isolated as a white powder exhibiting negative optical rotation (   2.24D  -26.07 (c 
0.33, MeOH)). The IR spectrum showed absorption bands in the region 1602, 1692 and 3369 cm-
1 attributable to the aromatic ring, carbonyl and hydroxyl groups, respectively. UV spectrum 
absorption maxima were observed at 304 (log 2.99), 259 (log  3.92) and 216 (log  4.27) nm. 
The molecular formula, C21H28O8, of 2 was determined by the quasi-molecular ion peak at m/z: 
409.1865 ([M+H]+, calcd. 409.1862) in the FT-ICR-MS spectrum (Fig. S14, SI1). Compound 2 
exhibited 1H and 13C NMR data closely resembling to those of 1. Comparison of the UV, IR and 
NMR spectroscopic data of 2 (Tables 1 and 4) with those of rhedynosin A (1) showed the 
following differences, the main one being the presence of an additional hexose sugar moiety 
having a signal for an anomeric-H at H 4.21 (d, J = 7.8 Hz) and remaining sugar proton signals 
at H 3.03-3.78. The 13C NMR spectrum of 2 contained an anomeric carbon signal of a hexose 
moiety at C 104.7 and signals for the remaining five sugar carbons at δC 62.7 - 78.1, which were 
in good agreement with those reported for glucoside compounds (Fukuoka et al., 1983). This 
indicated that compound 2 was a glycoside of compound 1. The coupling constant (J = 7.8 Hz) is 
consistent with trans 3JH-H, showing that it is a β-hexoside and that the adjacent proton on the 
sugar is axial in the chair conformation of the pyranose ring. The 8.9 Hz trans-diaxial coupling 
between H-2′ and H-3′ indicates an equatorial OH at C-3′. Thus, the sugar must be glucose or 
galactose. Since the 1H NMR signals for H-3′ and H-4′ overlap in the spectrum of 2, a sample was 
peracetylated forming the tetraacetate. The introduction of the electron withdrawing groups shifts 
the signals for the ring protons H-2′, H-3′, H-4′ and H-6′ downfield and resolves them clearly 
(method and spectra in SI1). The JH3′,H4′ coupling was determined to be ca. 8 Hz. This value is 
consistent with a trans-diaxial relationship between these protons in the chair conformation of the 
hexopyranose. Three trans-diaxial relationships derived from the ring protons of a pyranose are 
indicating a glucosyl residue. To our knowledge, no L-glucose has been reported being isolated 
from a plant source yet. Thus, it is most likely that this glycosyl residue belongs to the D-series. 
Carbon resonances at δC 104.7, 78.1, 77.9, 74.9, 71.5 and 62.7 in the 
13C NMR spectrum (Table 
4) provided further evidence for the presence of a glucopyranyl residue. The linkage position of 
the sugar moiety to C-11 of the aglycone was confirmed by an HMBC experiment, which shows 
correlations between the anomeric resonance H-1′ ( 4.21) and C-11 ( 75.0), and between H-11 
( 4.13 and 3.48) and the anomeric carbon C-1′ ( 104.7). The CD spectrum shows a plain positive 
n →π* component at ~330 nm that can be correlated with the configuration at C-2 being 2S 
(Kuroyanagi et al., 1979). Based upon the above evidence, the structure of 2 was identified as 
rhedynosin A 11-O--D-glucoside and named rhedynoside A (Fig. 1).  
A new natural product, compound 3, was isolated as a yellow powder with an accurate mass 
similar to 1 at m/z 247.0967 [M+H]+, consistent with a molecular formula of C14H15O4 and 8 
degrees of unsaturation. The IR bands were due to a hydroxyl, carbonyl and aromatic carbon-
carbon double bond observed at 3419, 1715 and 1603 cm-1, respectively. The 1H NMR spectrum 
(Table 1) of 3 closely resembles that of 1 but the 13C NMR (HMBC) data, displays only 14 carbon 
resonances instead of the 15 signals that appear in the spectrum of 1. These signals were ascribed 
to three methylenes, two methyls, one methine, six quaternary carbons and two carbonyl groups 
(Tables 1 & 4). The major difference in the NMR data for compound 3 is the absence of a 
methylene signal at  4.80 (CH2-12, 1H NMR) and the appearance of a quaternary carbon at C 
165.0 (13C NMR) corresponding to an ester, thus indicating that the methylene group (CH2-12) of 
1 is oxidised to a carbonyl in 3. This interpretation explains the downfield shift (H 8.05) of the 
methine signal (H-4) due to the influence of the carbonyl at position C-12. The HMBC spectrum 
confirmed the location of the carbonyl group. Furthermore, in the HMBC experiment strong 
correlations were observed from both proton signals at H 8.05 (H-4) & 4.55 (H-14) to the carbon 
signal at δC 165.0 (C-12). The other significant difference was the absence of CH2 signals at H 
3.78 and H 3.62 (CH2-11) in the 1H NMR spectrum. The 13C NMR spectrum showed that the 
methylene signal from C-11 was absent and that the signal for C-2 had moved downfield to C 
78.0, showing the presence of an oxygen. While CD spectra were obtained for 3, the absolute 
stereochemistry was not assignable as there was neither an X-ray reference with hydroxyl 
substitution on C-2 nor a previous literature report of a CD spectrum of a compound with a suitable 
chromophore core. Compound 3 was identified as a previously unreported natural product and 
named rhedynosin B (Fig. 1). 
Compound 4 was obtained as a white powder with an optical rotation   2.24D  +3.76. The negative 
mode mass spectrum showed a molecular ion peak at m/z 245.0821 [M-H]-, compatible with the 
molecular formula of C14H13O4. In the IR spectrum, strong bands at νmax 1703 and 3428 cm
-1 were 
indicative of carbonyl and hydroxyl groups, respectively. The maximum UV absorbances of 4 
appeared at 214, 258 and 306 nm, in agreement with 1-indanone compounds (Tanaka et al., 1982; 
Yoshihira et al., 1971). Analysis of the NMR and MS spectral data showed that 4 is structural 
similar to 3. The major differences were detected by NMR experiments, for example the presence 
of two isolated methylene signals at H 5.40 (2H, s, H-12) and H 3.83 (2H, s, H-13) which appear 
as singlets and thus indicated that the carbonyl group was at position 14 in 4. The chemical shift 
for CH2-12 (H 5.40) also indicated a very electron-deficient environment, consistent with 
ArCH2OC=O. The HMBC spectrum confirmed the assignments and connectivities, and also 
shows a cross peak between H-12 (H 5.40) and C-14 (C 173.5). The data provided further 
evidence for the carbonyl being present at the C-14 position. Thus, the structure of 4 was identified 
as a new compound, named rhedynosin C (Fig. 1). However, the absolute configuration in C-2 
remains undetermined. 
Compound 5 was obtained as a yellow solid. In the positive mode spectrum, pseudo-molecular 
ion peaks at m/z 269.0941 and m/z 271.0912 [M + H]+ in the ratio 3:1, indicate the presence of 
one chlorine atom and suggested a molecular formula of C14H18ClO3. The IR spectrum showed 
major absorption bands at 3418 cm-1 (OH), 1714 cm-1 (C=O) and 1602 and 1447 cm-1 (aromatic 
C=C). The UV spectrum exhibits UV signals at 212, 215 and 303 nm. The 1H NMR data (Table 
1) of 5 indicates a penta-substituted benzene ring with a single aromatic proton signal at H 7.39 
(1 H, s). Two coupled methylene groups at H 3.21 (2H, t, J = 8.0 Hz) and H 3.62 (2 H, t, J = 8.0 
Hz) indicate an ArCH2CH2X system, with the chemical shift of the latter triplet suggesting that X 
= Cl. The remaining 1H NMR signals were in agreement with a pterosin-type structure (Fukuoka 
et al., 1978; Kovganko et al., 2004; Kuraishi et al., 1985; Tanaka et al., 1982). The 13C NMR data 
of 5 (Table 4) shows fourteen distinct carbon environments, confirming the presence of a penta-
substituted aromatic ring, including a low-field signal at C 208.9 ppm (C=O) assigned as the C-1 
of a pterosin-type sesquiterpene skeleton. The HMBC proton-carbon correlations confirmed a 
pterosin K side chain, a 2-chloroethyl group (CH2CH2Cl) attached to C-6 of benzene ring. A 
singlet methylene signal at H 4.84 was assigned as the hydroxymethylene (CH2OH) group 
attached to C-5 of the benzene ring. All assignments were confirmed by HMBC correlations and 
5 was thus identified as rhedynosin D (Fig. 1). However, the absolute configuration in C-2 remains 
undetermined. 
Compound 6 was obtained as an off-white powder and its molecular formula was determined from 
the positive mode FT-ICR-MS to be C15H19O4 (m/z 263.1280 [M+H]
+, calcd 263.1283). The UV, 
IR, and NMR data of 6 were very similar to histiopterosin A (28) (Murakami et al., 1980). Two 
carbonyl resonances were evident in the 13C NMR spectrum, with the ketone signal at C 211.6 
and a carboxylic acid signal at C 175.3. In the 1H NMR spectrum of 6, an additional methyl signal 
is present, which was shown to be connected to C-2 by HMBC. Thus, two magnetically 
inequivalent methyl groups are attached to C-2, which resonate as singlets at H 1.05 and H 
1.19.The application of CD spectroscopy to compound 6 showed a non-vibronic n→π* transition 
which was compared to the CD spectrum for 19 reported by Kuroyanagi et al., 1979 and assigned 
the configuration as S on C-3. Therefore, the structure of 6 was confirmed as rhedynosin E (Fig. 
1). 
Compound 8 was obtained as a yellow gum. In the FT-ICR-MS, 8 gave the same molecular 
formula as 5 (C14H17ClO3). The UV spectrum showed absorption bands at 218, 260 and 299 nm. 
The IR, NMR and MS data of 8 were similar to those of 5, with detailed exceptions which allowed 
identification of 8. Differences were found in the NMR signals for the C-12 and C-13 positions 
for these two compounds. The 1H NMR spectrum of 8 showed a methyl group resonating at H 
2.55 that gave a proton-carbon correlation to the carbon resonating at C 22.0 in the HSQC 
spectrum and by HMBC this was assigned as C-12. A methine group, resonating at H 5.45 (1 H, 
dd, J = 5.2, 8.7 Hz), that gave proton-carbon correlation to the carbon resonating at C 71.4 in the 
HSQC spectrum, was assigned as the C-13. This suggested that the hydroxy group, which had 
been at C-12 in 5, was in position C-13 in 8. Compound 8 was thus identified as rhedynosin G 
(Fig. 1). However, the absolute configuration in C-2 remains undetermined. 
Compound 7 was obtained as a pale yellow crystalline powder. In the accurate mass spectrum, 7 
gave the molecular formula C15H19ClO3, suggesting an additional methylene group when 
compared to 8. The UV, IR and NMR data were similar to those of 8. However, the additional 
methylene group was evident from the NMR data of 7, with two geminally coupled doublets H 
3.79 (1 H, d, J = 10.7 Hz) and H 3.59 (1 H, d, J = 10.7 Hz), correlating through one-bond with a 
new carbon signal at C 68.1. The chemical shifts indicated that this new methylene was attached 
to the oxygen and thus the hydroxymethylene group was in position C-2. On the basis of the above 
mentioned evidence, the structure of 7 was confirmed as rhedynosin F (Fig. 1). CD spectroscopy 
allowed a 2S assignment of configuration. 
Compound 9 was isolated as an off-white powder and its mass spectrum in the negative ion mode 
showed a molecular ion peak at m/z 297.0802 [M-H]- corresponding to a molecular formula of 
C14H17O5S (calcd as 297.0797). The UV, IR, and NMR data of 9 were very similar to those of 
pterosin B (16) (Fig. 3). This molecular formula suggested that the primary alcohol of 16 had been 
sulfated. This was confirmed by a downfield shift of the 1H NMR resonance for the adjacent CH2 
(CH2-14) to H 4.05. Sulfated monoesters are common in marine natural products (McKee et al., 
1994; Uddin et al., 2011). Compound 9 and 12 were subjected to CD spectroscopy, however, no 
significant spectra were observed and it is hypothesised that 9 and 12 racemised due to the 
presence of an acidic proton in the α-position to the carbonyl group. The structure of 9 was 
confirmed by full analysis of the data as rhedynosin H (Fig. 1). 
 
Compound 10, obtained as a white crystalline product, exhibited a molecular ion peak at m/z 
415.1527 [M+H]+ in the mass spectrum and correlated to the molecular formula C20H28ClO7 (calcd 
as 415.1523). The UV, IR, and NMR data for 10 was very similar to that reported for pterosin F 
(21) (Fukuoka et al., 1978; Kuroyanagi et al., 1979), except for the presence of a sugar moiety in 
10 which was connected to the aglycone through C-2, as determined by the HMBC experiment. 
Careful study of the coupling constants around the hexopyranose in the 1H NMR spectrum 
suggested that the sugar was a glucose; J1′,2′ = 7.8 Hz, J2′,3′ = 8.0 Hz and J3′,4′ = 8.9 Hz, consistent 
with trans-diaxial arrangements of these protons. X-ray crystallography confirmed 10 as 
rhedynoside B and assigned the configuration at C-2 as R (Figs. 2 & 8). 
Compound 11 was obtained as an off-white crystalline powder. In the FT-ICR-MS, 11 was shown 
to have the molecular formula C21H29ClO7, with a molecular mass 14 Da higher than 10. The UV, 
IR and NMR data of 11 were similar to those of pterosin H (Hayashi et al., 1972; Padwa et al., 
1996; Tanaka et al., 1982) with the exception that 11 contained a sugar moiety. Of particular 
interest was a pair of geminally coupled doublets in the 1H NMR spectrum at H 5.11 (1 H, d, J = 
12.4 Hz) and H 4.78 (1 H, d, J = 12.4 Hz). These signals gave a one-bond H-C correlation with 
the 13C NMR signal at C 70.2. The chemical shifts corresponded to an ArCH2O system. An 
HMBC experiment assigned this carbon signal being connected to C-12. Moreover, the HMBC 
also linked the sugar to this methylene. The 1H NMR spectrum of 11 confirmed the sugar as a 
hexopyranoside and identified the configuration of the glycosidic bond as , with J1′,2′ = 7.7 Hz 
(also suggesting that the sugar was glucose or galactose). Peracetylation of the sugar separated the 
1H NMR signals of the sugar sufficiently to provide a full diastereomeric assignment of the sugar 
as glucose (see the discussion for 2 above). On the basis of this evidence, compound 11 was 
identified as rhedynoside C (Fig. 1). 
Compound 12, a novel natural product, was obtained as a yellow powder with the negative optical 
rotation   6.24D  -0.643 (c 0.33, MeOH). In the FT-ICR-MS, 12 gave a quasi-molecular ion peak at 
m/z 413.1374 [M-H]-, appropriate for a molecular formula C20H26ClO7 (calcd as 413.1367), and 
indicating that it was an isomer of 10. The UV, IR and NMR data of 12 were broadly similar to 
those of 10 except that the point of attachment of the sugar was clearly different. As for 11, a 
diastereotopic methylene group was observed in the NMR spectra at H 5.10 (1 H, d, J = 12.3 Hz) 
& 4.78 (1 H, d, J = 12.3 Hz) and C 70.2. Using the same rationale as for determination of the 
location of the sugar as for 11, HMBC data confirmed that the sugar was attached through a 
glycosidic linkage to C-12. Examination of the 1H NMR coupling constants for protons around 
the hexopyranose in native and peracetylated forms demonstrated that it was -linked glucose. 
Also notable was the presence of only one methyl group at C-2, H 1.25 (3 H, d, J = 7.2 Hz), with 
the 13C NMR signal for C-2 now reported as a methine. The structure of 12 was thus established 
as rhedynoside D (Fig. 1). However, the absolute configuration in C-2 remains undetermined. 
Compound 13 was isolated as an off-white crystalline powder. Its molecular formula, C21H29ClO7, 
was deduced from the FT-ICR-MS, indicating that it was another isomer of 11. The UV, IR and 
NMR data for the aglycone of 13 were very similar to those of (3R)-hydroxypterosin H (Tanaka 
et al., 1982) indicating that it has the same structure in the aglycone part. A NOESY study of 
compound 13 showed through-space correlations between H-1′ and H-3′ and between H-1′ and H-
5′, confirming that these three protons are all axial and that the sugar is glucose. Singlet signals 
for three methyl groups were evident in the 1H NMR spectrum, with HMBC confirming that two 
methyl signals (H 1.28 and H 1.09) formed a geminal pair. The third (H 2.49) was in an ArMe 
environment and was confirmed by HMBC data to correspond to C-12. The signal for H-3 was 
identified as being at H 4.85, appropriate to ArCHO. HMBC correlations from H-3 (H 4.85, s) 
to C-1′ (C 105.9), and from H-1′ (H 4.58, d, J = 7.7 Hz) to C-3 (C 86.10) evidence that the 
glycosyl residue is connected through C-3 (Fig. S113, Supplementary Information 1). The 
application of CD spectroscopy to compound 13 shows a non-vibronic n→π* transition which is 
opposite to the transition observed for 6. Based on the comparison of CD data of 13 to that for 19 
reported by Kuroyanagi et al., 1979, 13 was assigned the R configuration in C-3. The reported 
compounds, 13-chloro-spelosin 3-O-β-D-glucopyranoside (Chen et al., 2015) and (2R,3R)-
pterosin L 3-O-β-D-glucopyranoside (Chen et al., 2008), whose 1H and 13C NMR data are very 
similar to compound 13, also show R configuration in C-3. As a result of these observations, 13 
was identified as rhedynoside E (Fig. 1). 
2.2. Structural Relationships between New and Known Pterosins and Pterosides 
Rhedynoside B (10) is the first example of a pteroside bearing the glucose moiety at the position 
C-2 and hence being directly attached to the five membered ring in α-position to the keto group. 
In addition, this is also the first report of glycosylation at C-12 with the 12-O-β-D-glucopyranoside 
substituted pterosins: rhedynosides C (11) and D (12). Most previously reported pterosides have 
had the sugar moiety at the following positions: C-11, for example, pterosides A2 and K (Castillo 
et al., 2003; Kuroyanagi et al., 1979); C-14, such as pterosides A, B, C, D, P and Z (Hikino et al., 
1972, 1971; Kuroyanagi et al., 1979) or C-3, e.g. (2R, 3R)-pterosin L 3-O-β-D-glucopyranoside 
(Chen et al., 2008) and (2S, 3S)-pterosin C 3-O-β-D-glucoside (wallichoside) (Sengupta et al., 
1976). Furthermore, rhedynosin A (1) and rhedynoside A (2) are novel compounds, being the first 
examples of a six-membered cyclic ether containing pterosin and pteroside.  
For the first time rhedynosin C (4) was isolated from the rhizomes of P. aquilinun (L.) Kuhn, as a 
new cyclic lactone pterosin with a keto group at position C-14. However, another cyclic lactone 
pterosin, (S)-12-hydroxy-2-hydroxymethylpterosin E 14, 12-lactone, with one extra methylene has 
been reported as a metabolic product of (2S)-pterosin A in rat urine via oral administration (100 
mg/kg)  (Lee et al., 2012). Other metabolites of (2S)-pterosin A were compounds 14, 27 and 29, 
which we isolated for the first time from plant material. We hence suggest rhedynosin I as common 
name for compound 14. Moreover, (2S)-pteroside A2 and histiopterosin A are being reported for 
the first time from the rhizomes of subsp. aquilinum of bracken fern, as they have previously been 
isolated from the young fronds of P. aquilinum (L.) Kuhn var. caudatum (syn Pteridium caudatum 
L. Maxon) (Castillo et al., 2003) and Histiopteris incisa (Murakami et al., 1980), respectively. 
More interestingly, a novel sulfated-pterosin, rhedynosin H (9), was isolated from belowground 
rhizomes of P. aquilinum (L.) Kuhn. Previously, (2R, 3S)-sulfated pterosin C and (2S, 3S)-sulfated 
pterosin C have been reported from the aerial parts of Acrostichum aureum (Uddin et al., 2011). 
The absolute stereochemistry of the novel compound rhedynoside B (10) was determined by single 
crystal X-ray diffraction analysis (Figs. 2 & 8, and SI2). The CD spectrum of 15 exhibited negative 
and positive vibronic components associated with the n→π* transition in the range of 320-360 nm 
(Fig. 6). Thus, compound 15 was assigned 2S configuration (Kuroyanagi et al., 1979) and 
confirmed by X-ray diffraction (Fig. 7). The n→π* CD components of compounds 17 and 18 
exhibit a strong negative Cotton effect around 330 nm (Fig. 9) which is in agreement with the 
reported CD data and thus, the configurations of 17 and 18 were determined to be 2R, 3R and 2S, 
3R (Kuroyanagi et al., 1979). Again, X-ray diffraction confirmed this (Fig. 7). X-ray data for the 
two known pterosides (31 and 35) confirmed the absolute configuration determined previously by 
CD, i.e. (2R)-pteroside B (31) and (2S)-pteroside K (35) (Fukuoka et al., 1978; Kuroyanagi et al., 
1979; Ng and McMorris, 1984) (Figs. 2 & 7, SI2, and deposited with the Cambridge 
Crystallographic Data Centre).  
The pterosins and pterosides isolated from bracken rhizomes showed surprising structural 
diversity, which even encompassed chloride and sulphate substituents. The biosynthesis of 
pterosin B is thought to be derived from the sesquiterpenoid biosynthetic pathway established by 
using the incorporation of radiolabelled mevalonate. Specifically Hikino et al. (1976) suggested 
pterosin B (16) to be derived from mevalonic acid via farnesyl pyrophosphate and humulene. It is 
hypothesised that at least compounds 9 and 12 derive from ptaquiloside degradation in planta as 
the major ptaquiloside degradation product, pterosin B (16), originates from a nucleophilic 
addition of present nucleophiles. The less abundant nucleophiles in planta Cl- and SO4
2- can also 
act by a similar mechanism to yield the chlorinated rhedynosins (5, 7 and 8) and rhedynosides (10-
13). Their presence in crude rhizome extracts, using MeOH and Et2O instead of chloroform, was 
confirmed by HPLC/ESI-MSn analysis. Both negative molecular ions (427 and 429 Da) of 
compounds 11, 13 and 35 showed a constant neutral loss of 162 Da to give ions at m/z 265 and 
267, respectively, which corresponded to the loss of an O-linked hexose moiety (glucose) (Felipe 
et al., 2014; Levandi et al., 2014; Qu et al., 2004; Scholz et al., 2005) (Figs. SD1-4, Supplementary 
Data 2). The presence of only one sulfated metabolite amongst the group of reported pterosins is 
rather a degradation product than a compound of biosynthetic origin. The other reported sulfated 
pterosins (Uddin et al., 2011) occurred as both trans and cis isomers at C2-C3, which also suggests 
their origin from degradation of ptaquiloside rather than through direct biosynthesis (Yamada et 
al., 2007). Similarly, cis and trans motifs at C2-C3 were identified in compounds 17 and 18 (Figs. 
2 & 7). The C-2 position adjacent to the keto group readily epimerises if there is simply a methyl 
substituent. Unfortunately, at this stage it was not possible to assign the absolute configurations 
for compounds 9, 12, 16, 20, 21, 25, and 31. A hydroxymethyl group at C-2 is apparently optically 
stable as in compounds 1, 2, 7, 14, 15, 23, 27, 29, 30, 34 and 35. Epimerisation may well be 
inhibited through intermolecular hydrogen bonding in these compounds (Kuroyanagi et al., 1979).  
 
2.3. Biological Activity Assessment 
Hsu et al. (2014) patented the use of pterosins and pterosides, including 86 distinct compounds of 
natural and synthetic origin. Their biological activity for treating diabetes and obesity was 
investigated predominantly with pterosin A but claimed for all described compounds. On this basis 
we were particularly interested whether pterosins or pterosides were more active. Hence a 
selection of pterosins (15 - 17) and their associated pterosides (30, 31 and 33) were assessed for 
their anti-diabetic activity using an intestinal glucose uptake assay in vitro, specifically seeking 
inhibitors of the SGLT1 and GLUT2 transporters. However, no compound was active at 300 M 
(more details can be found in the Supplementary Data 2) in contrast to activity reported by Hsu et 
al. (2014). However, Hsu et al. (2014) studied the antidiabetic activity for extracts of bracken 
against STZ-induced disease in mice at 100 mg/Kg/d for 14 days by activating GLUT4. Thus, the 
discrepancy could have multiple origins, including the dosing schedule and activity in the latter 
assay through a mechanism other than through SGLT1 and GLUT2 transporters. 
3. Conclusion 
This study describes the successful isolation and identification of 35 pterosin-type 
sesquiterpenoids from the rhizome of Pteridium aquilinum (L.) Kuhn, including eight new 
pterosins (1 & 3-9) and five new pterosides (2 & 10-13). Their chemical structures were elucidated 
by 1D and 2D NMR spectroscopic analysis. The absolute configuration were also determined for 
five compounds by using either single crystal X-ray diffraction (10) or CD spectroscopy (15, 31, 
35) or both techniques (17, 18). In addition, CD spectroscopy yielded the absolute configuration 
for 1, 2, 6, 7, and 13. To the best of our knowledge, rhedynosides C (11) and D (12) are the first 
reported glucosides with the glucose moiety on the C-12 of the aglycone. In addition, one 
previously unreported sulfate-containing pterosin, rhedynosin H (9), together with two other 
reported compounds, histiopterosin A (28) and (2S)-pteroside A2 (34), were isolated for the first 
time from the rhizomes of bracken, subsp. aquilinum. Furthermore, compounds 1 and 2 have a 
relatively rare aglycone, containing a six-membered cyclic ether.  
 
4. Experimental 
4.1. General experimental procedures: 
1D and 2D NMR spectra were recorded on a Bruker Avance (DRX) instrument (Bruker BioSpin 
Group, Germany) (400 or 500 MHz) NMR spectrometer in CD3OD, CDCl3, or (CD3)2CO with 
TMS as internal standard. Ultra-high mass accuracy analysis was performed on a Nano-Flow 
(Triversa Nanomate; Advion biosciences limited, Norfolk, UK) linear trap quadrupole Fourier 
Transformation Ion Cyclotron Resonance Mass Spectrometry Ultra (FT-ICR-MS), where ultra 
refers to the high sensitivity ICR cell. Samples were reconstituted in 100 µL of HPLC grade MeOH 
/ ultra-pure water (7:3). Samples were vortexed, and were centrifuged for 4 min, at 13,000 rpm at 
a temperature of 0 ºC. 20 µL of supernatant was then transferred to a clean well on a 128-well 
plate. 13 µL of sample was injected by the nano-flow injection system, with a 5 µL aliquot being 
delivered to the ICR cell. Gas pressure was maintained at 0.5 psi with an applied voltage of 1.5 
kV to maintain a consistent current of 60-120 nA. When operating in narrow SIM mode, the 
resolution was 100,000 and the scan window 30 m/z. Each scan window was acquired in 60 s. 
Specific rotations were acquired using ADP 440+ Polarimeter (Bellingham + Stanley Ltd). IR 
spectra were recorded on a PerkinElmer Spectrum 100 FT-IR Spectrometer using NaCl disc, and 
the samples were prepared as a solution. Column chromatography (CC) used silica gel (LC60A 
40-63 MICRON, Germany). UV spectra were recorded on PerkinElmer (Singapore) Lambda 35 
UV/VIS Spectrometer. 
CD spectra for the compounds were recorded at 25 °C using a Chirascan CD spectrometer 
(Applied Photophysics Ltd). Samples (~1 mg/ml) were measured in methanol using a 1 mm 
pathlength quartz cuvette. Data were recorded every 0.5 nm between 280 nm and 400 nm with a 
1 nm spectral bandwidth and an integration time of 2 seconds per data point. 
Chromatographic profiling, method development and assessment of purity of isolated pterosins 
and pterosides from each fraction of bracken rhizome chloroform extract were performed using a 
Dionex UltiMate 3000 HPLC system from Thermo Scientific equipped with Binary gradient 
pump, Autosampler and diode array detector (DAD) monitoring 190-400 nm (UV-VIS detector). 
Chromatographic analysis of each fraction was achieved using reverse phase analytical column, 
250 × 4.6 mm, packed with Spherisil ODS-2 (C18), 5µm as a stationary phase. Different ratios of 
two mobile phases of MeOH-H2O and ACN-H2O (acidified with 0.1% formic acid) at a flow rate 
of 1.0 mL/min at 40 °C were used to obtain high resolution chromatograms. Ultraviolet detection 
was set at 254 nm. The Chromeleon 7 Software was used to control gradient setting, data 
acquisition and auto-sampler. 
The Reveleris® Flash Chromatography system was used for purification of pterosins and 
pterosides. The samples were pre-adsorbed onto silica gel and subsequently run on the Reveleris® 
C18 (40 µm, 12 g) column for 64 min using two different solvent systems, MeOH-H2O and ACN-
H2O (acidified with 0.1% formic acid), at a flow rate of 18 mL/min. The peaks were visualised 
and recorded with UV-Vis (254 nm and 280 nm) and ELSD detectors.  
Preparative TLC was conducted using glass plates pre-coated with silica gel (TLC Silica gel 60 
F254, Germany, 1.0 mm thickness, 20 × 20 cm). Mixture of chloroform extract fractions were 
applied to TLC plates using suitable solvent systems. These compounds were visualized using 
UV-light and / or phosphomolybdic acid (PMA). 
Single crystal X-ray diffraction data were collected either on a Rigaku AFC11 quarter chi 
goniometer equipped with an enhanced sensitivity (HG) Saturn944+ detector mounted at the 
window of 007 HF copper rotating anode generator with Varimax optics (cis-pterosin C, trans-
pterosin C and (2S)-pterosin A), or on a Rigaku AFC12 goniometer equipped with an enhanced 
sensitivity (HG) Saturn724+ detector mounted at the window of an FR-E+ SuperBright 
molybdenum rotating anode generator with VHF Varimax optics (70 µm focus) ((2R)-pteroside 
B, (2S)-pteroside K and rhedynoside B). Rigaku CrystalClear (Rigaku Corporations, The 
Woodlands, Texas, USA) was used to record images. Data integration was carried out using 
Agilent CrysAlisPro (Agilent- Technologies UK Ltd). (cis-pterosin C, trans-pterosin C, (2S)-
pterosin A and rhedynoside B) or Rigaku CrystalClear ((2R)-pteroside B, (2S)-pteroside K). The 
structures were solved by charge-flipping methods using SUPERFLIP (Palatinus and Chapuis, 
2007) and refined on Fo
2 by full-matrix least squares refinement using SHELXL-2014 (Sheldrick, 
2008). All non-hydrogen atoms were refined with anisotropic displacement parameters. Hydrogen 
atoms were added at calculated positions and refined using a riding model with isotropic 
displacement parameters based on the equivalent isotropic displacement parameter (Ueq) of the 
parent atom. The structures were deposited on the Cambridge Structural Database with the 
deposition numbers CCDC 1050917, 1050918, 1050920, 1406891, 1418452 and 1418453. 
In order to confirm the presence of isolated chlorinated compounds, bracken rhizomes (10 g, dry 
weight) were extracted with 100 ml of methanol and ethyl acetate, and the extracts were analysed 
by reverse-phase HPLC using photodiode array detection with and without electrospray 
ionisation-ion trap mass spectrometry (HPLC/ESI-MSn) (more details are in the SI2). 
 
4.2. Plant material 
The bracken rhizomes (11.8 kg) were collected from Llanberis in Wales N 53o 07′ and W 04o 08′, 
on 21 February 2013. They were confirmed as Pteridium aquilinum (L.) Kuhn by Nigel Brown. 
A voucher specimen was deposited at Treborth Botanical Garden, Bangor. 
4.3. Extraction and isolation  
The air-dried chopped bracken rhizomes (3.45 kg) were macerated with chloroform (14 L) at room 
temperature for 3 × 24 h. After filtration, the organic solvent was reduced under pressure to give 
the crude extract (7.1 g) which was pre-adsorbed onto silica gel and subjected to CC using CHCl3-
MeOH mixture with increasing polarity (100:0 → 0:100) to give thirteen fractions (BR1-BR13). 
From these fractions, 13 new compounds (1, 6.0 mg; 2, 11.0 mg; 3, 5.8 mg; 4, 2.6 mg; 5, 4.5 mg; 
6, 6.0 mg; 7, 4.1 mg; 8, 13.0 mg, 9, 3.0 mg; 10, 11.6 mg; 11, 3.2 mg; 12, 9.1 mg, and 13, 3.8 mg) 
and 22 known compounds (14, 6.0 mg; 15, 160.0 mg; 16, 110.0 mg; 17, 18.0 mg; 18, 20.0 mg; 19, 
60.0 mg; 20, 17.0 mg; 21, 10.0 mg; 22, 5.0 mg; 23, 3.0 mg; 24, 15.4 mg; 25, 4.0 mg; 26, 14.0 mg; 
27, 14.7 mg; 28, 3.0 mg; 29, 4.0 mg; 30, 10.2 mg; 31, 203.0 mg; 32, 4.9 mg; 33, 47.0 mg; 34, 4.2 
mg and 35, 30.0 mg) were isolated as the following: 
Preparative TLC was applied to purify fraction BR1 (25.0 mg) using n-hexane-acetone (1:9) to 
give 21 (10.0 mg). Fraction BR2 (350 mg) was further chromatographed on a silica gel column 
eluting with gradient of n-hexane-EtOAc (100:0 → 45:55) to obtain five sub-fractions (BR2A-
BR2E). Sub-fraction BR2A (170.0 mg) was subjected to RP-FC using a gradient elution of ACN-
H2O (35-45%, 1 h) to give 20 (17.0 mg); 22 (5.0 mg); 23 (3.0 mg) and 26 (14.0 mg). Sub-fractions 
BR2B (130.0 mg), BR2D (20.0 mg) and BR2E (10 mg) were each subjected to preparative TLC 
using n-hexane-EtOAc (4:6), EtOAc and MeOH-Et2O (1:49) to give 16 (110.0 mg), 14 (6.0 mg) 
and 4 (2.6 mg), respectively. Sub-fraction BR2C (22 mg) was purified using preparative TLC 
(diethyl ether) to afford compounds 1 (6.0 mg) and 3 (5.8 mg). Fractions BR3 (128.9 mg) and 
BR4 (37 mg) were purified separately by preparative TLC using n-hexane-acetone (1:1 and 6:4) 
to afford 8 (13.0 mg) and 7 (4.1 mg), respectively. Preparative TLC (diethyl ether) was applied to 
fraction BR5 (109 mg) to afford 5 (4.5 mg) and 24 (15.4 mg). Fraction BR6 (375 mg) was 
fractionated by applying it on RP-FC with an isocratic gradient elution (20-20%, ACN-H2O, 1 h) 
to give 15 (160.0 mg) and 19 (60.0 mg). Fraction BR7 (600 mg) was resolved by a silica gel CC 
eluted with gradients of n-hexane-EtOAc and EtOAc-MeOH with increasing polarity, 
respectively, to yield four sub-fractions (BR7A-BR7D). Sub-fraction BR7A (51.5 mg) was 
chromatographed on RP-FC using a gradient elution of ACN-H2O (20-23%, 1 h) to afford 6 (6.0 
mg) and 27 (14.7 mg). RP-FC was applied on sub-fraction BR7B (33.0 mg) using ACN-H2O (20-
23%, 1 h) as a gradient elution to obtain 28 (3.0 mg). Sub-fraction BR7C (242.0 mg) was subjected 
to RP-FC using a gradient elution of ACN-H2O (20-23%, 1 h) to obtain four main fractions 
(BR7C1-BR7C4), and then the second peak (BR7C2) (38 mg) was further chromatographed on 
RP-FC using  a gradient elution of ACN-H2O (06-06-10-11%, 2 h) to afford 17 (16.5 mg) and 18 
(19.5 mg). Sub-fraction BR7D (97.0 mg) was resolved on RP-FC using a gradient elution of ACN-
H2O (15-20%, 1 h) to give 25 (4.0 mg). Fraction BR8 (119.7 mg) was subjected to RP-FC using 
a gradient elution of MeOH-H2O (40-50%, 1 h) to give 10 (11.6 mg) and 29 (4.0 mg). Fraction 
BR9 (110 mg) was separated with RP-FC using a gradient elution of MeOH-H2O (40-50%, 1 h) 
to obtain four sub-fractions (BR9A-BR9D). Sub-fractions BR9A, BR9B and BR9D gave 11 (3.2 
mg), 12 (9.1 mg) and 35 (30.0 mg), respectively. The purification of sub-fraction BR9C (15.0 mg) 
on RP-FC using gradient elution (25-30% ACN-H2O, 1 h) yielded 13 (3.8 mg). Fraction BR11 
(261.7 mg) was resolved on RP-FC using MeOH-H2O (40-50%, 1 h) as a mobile phase to obtain 
2 (11.0 mg), 31 (203.0 mg) and 33 (47.0 mg). Fraction BR13 (200 mg) was further fractionated 
by applying it to RP-FC with a gradient elution (10-25% ACN-H2O, 1 h) to obtain four sub-
fractions (BR13A-BR13D). Compounds 32 (4.9 mg), 30 (10.2 mg) and 34 (4.2 mg) were obtained 
from sub-fractions BR13A, BR13B and BR13C, respectively, while sub-fraction BR13D (30 mg) 
was re-subjected to RP-FC using a gradient elution (40-50% ACN-H2O, 1 h) to afford 9 (3.0 mg). 
4.4. Physico-chemical parameters of the new compounds 
Rhedynosin A (1); Yellow powder;  24D  -4.31 (c 0.33, CHCl3); UV (MeOH) max nm (log ): 
211 (4.16), 241 (3.77), 258 (3.85), 306 (2.99); IR (film) νmax 3418, 3014, 2928, 1704, 1605, 1446, 
1380, 1048, 755, 666 cm-1; for 1H and 13C NMR spectroscopic data, see Tables 1 & 4; FT-ICR-
MS m/z 247.1330 [M+H]+ (calcd for C15H19O3, 247.1334).  
Rhedynoside A (2): White powder;   2.24D  -26.07 (c 0.33, MeOH); UV (MeOH) max nm (log 
): 216 (4.27), 259 (3.92), 304 (2.99); IR (film) νmax 3369, 2927, 1692, 1602, 1444, 1378, 1075, 
918 cm-1; for 1H and 13C NMR spectroscopic data, see Tables 1 & 4; FT-ICR-MS m/z 409.1865 
[M+H]+ (calcd for C21H29O8, 409.1862). 
Rhedynosin B (3): Yellow powder;  24D  -12.78 (c 0.33, CHCl3); UV (MeOH) max nm (log 
): 209 (4.31), 260 (3.96), 313 (3.09); IR (film) νmax 3419, 3018, 2926, 1715, 1603, 1446, 1379, 
1290, 1196, 1096, 985, 856, 754, 666 cm-1; for 1H and 13C NMR spectroscopic data, see Tables 1 
& 4; FT-ICR-MS m/z 247.0967 [M+H]+ (calcd for C14H15O4, 247.0970). 
Rhedynosin C (4): White powder;   2.24D  +3.76 (c 0.33, MeOH); UV (MeOH) max nm (log ): 
214 (3.24), 242 (2.97), 258 (2.94), 306 (2.51); IR (film) νmax 3428, 2924, 1703, 1608 1458, 1379, 
1260, 1034, 800 cm-1; for 1H and 13C NMR spectroscopic data, see Tables 1 & 4; FT-ICR-MS m/z 
245.0821 [M-H]- (calcd for C14H13O4, 245.0814). 
Rhedynosin D (5): Yellow solid;  24D  -19.12 (c 0.33, CHCl3); UV (MeOH) max nm (log ): 
215 (4.13), 259 (3.75), 303 (2.76); IR (film) νmax 3418, 2925, 1714, 1602, 1447, 1379, 1093, 855, 
756, 666 cm-1; for 1H and 13C NMR spectroscopic data, see Tables 1 & 4; FT-ICR-MS m/z 
269.0941 [M+H]+ (calcd for C14H18
35ClO3, 269.0944). 
Rhedynosin E (6): Off-white powder;   2.24D  -14.94 (c 0.33, MeOH); UV (MeOH) max nm (log 
): 217 (4.35), 258 (4.02), 295 (3.13); IR (film) νmax 3419, 2932, 1699, 1600, 1465, 1382, 1203, 
1099, 995, 884 cm-1; for 1H and 13C NMR spectroscopic data, see Tables 2 & 4; FT-ICR-MS m/z 
263.1280 [M+H]+ (calcd for C15H19O4, 263.1283). 
Rhedynosin F (7): Light yellow crystalline powder;  24D  +15.36 (c 0.33, CHCl3); UV (MeOH) 
max nm (log ): 219 (4.27), 259 (3.87), 298 (2.92); IR (film) νmax 3417, 2929, 1698, 1598, 1455, 
1379, 1223, 1042, 923, 859, 755 cm-1; for 1H and 13C NMR spectroscopic data, see Tables 2 & 4; 
FT-ICR-MS m/z 283.1098 [M+H]+ (calcd for C15H20
35ClO3, 283.1101).  
Rhedynosin G (8): Yellow gum;   2.24D  +4.04 (c 0.33, MeOH); UV (MeOH) max nm (log ): 
218 (4.34), 260 (3.97), 299 (3.03); IR (film) νmax 3405, 2929, 1705, 1599, 1447, 1378, 1217, 1094, 
983, 887, 751 cm-1; for 1H and 13C NMR spectroscopic data, see Tables 2 & 4; FT-ICR-MS m/z 
269. 0941 [M+H]+ (calcd for C14H18
35ClO3, 269.0944). 
Rhedynosin H (9): Off-white powder;  24D  -28.049 (c 0.33, CHCl3); UV (MeOH) max nm 
(log ): 217 (4.71), 258 (4.37), 303 (3.55); IR (film) νmax 2919, 1704, 1601, 1456, 1377, 1325, 
1221, 1129, 1020, 970, 885, 756, 702 cm-1; for 1H and 13C NMR spectroscopic data, see Tables 2 
& 4; FT-ICR-MS m/z 297. 0802 [M-H]- (calcd for C14H17O5S, 297.0797). 
Rhedynoside B (10): White crystalline compound;   2.24D  -10.82 (c 0.33, MeOH); UV (MeOH) 
max nm (log ): 219 (4.48), 263 (4.12), 304 (3.11), nm; IR (film) νmax 3391, 2926, 1703, 1601 
1451, 1376, 1327, 1227, 1074, 918, 872 cm-1; for 1H and 13C NMR spectroscopic data, see Tables 
3 & 4; FT-ICR-MS m/z 415.1527 [M+H]+ (calcd for C20H28
35ClO7, 415.1523). 
Rhedynoside C (11): Off-white crystalline powder;   6.24D  -0.488 (c 0.33, MeOH); UV (MeOH) 
max nm (log ): 216 (4.43), 257 (3.98), 303 (2.93); IR (film) νmax 3391, 2927, 1699, 1601, 1440, 
1379, 1326, 1077, 918, 888 cm-1; for 1H and 13C NMR spectroscopic data, see Tables 3 & 4; FT-
ICR-MS m/z 427.1530 [M-H]- (calcd for C21H28
35ClO7, 427.1524). 
Rhedynoside D (12): Yellow powder;   6.24D  -0.643 (c 0.33, MeOH); UV (MeOH) max nm (log 
): 216 (4.43), 256 (4.01), 303 (2.98); IR (film) νmax 3374, 2928, 1700, 1600, 1440, 1376, 1312, 
1163, 1075, 921, 890 cm-1; for 1H and 13C NMR spectroscopic data, see Tables 3 & 4; FT-ICR-
MS m/z 413.1374 [M-H]- (calcd for C20H26
35ClO7, 413.1367). 
Rhedynoside E (13): Off-white crystalline powder;   6.24D  +0.436 (c 0.33, MeOH); UV (MeOH) 
max nm (log ): 218 (4.40), 258 (3.92), 300 (2.63); IR (film) νmax 3390, 3018, 2928, 1703, 1599, 
1462, 1380, 1325, 1162, 1076, 898, 757 cm-1; for 1H and 13C NMR spectroscopic data, see Tables 
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Formula: C14H18O3; Mr = 234.28; crystal dimensions: 0.41 x 0.07 x 0.04 mm;  
crystal system: Monoclinic; space group: P21; a = 4.58360(6) Å, b = 
15.93341(16) Å, c = 8.13657(8) Å, α = 90o, β = 93.1583(10)o, γ = 90o; V = 
593.330(11) Å3; Z = 2; ρcalcd = 1.331 Mg/m3; μ = 0.736 mm-1; Cu Kα radiation, 
λ = 1.54184 Å; T = 100 K; 2Θmax = 138.0; 20930/2179 
measured/independent reflections; Rint: 0.0516; Flack parameter/Hooft 
parameter -0.03(9)/-0.12(4); R = 0.0285, wR = 0.0752; Δρmax = 0.133 eÅ−3, 








Formula: C14H18O3; Mr = 234.28; crystal dimensions: 0.15 x 0.12 x 0.10 mm;  
crystal system: Orthorhombic; space group: P212121; a = 7.07508(11) Å, b = 
11.4381(2) Å, c = 14.9966(2) Å, α = 90o, β = 90o, γ = 90o; V = 1213.61(4) Å3; 
Z = 4; ρcalcd = 1.282 Mg/m3; μ = 0.719 mm-1; Cu Kα radiation, λ = 1.54184 
Å; T = 100 K; 2Θmax = 138.5o; 14992/2138 measured/independent 
reflections; Rint: 0.0563; Flack parameter/Hooft parameter 0.11(13)/0.05(9); 
R = 0.0301, wR = 0.0779; Δρmax = 0.147 eÅ−3, Δρmin = −0.119 eÅ−3. 







Formula: C15H20O3; Mr = 248.31; crystal dimensions: 0.64 x 0.31 x 0.06 mm;  
crystal system: Monoclinic; space group: P212121; a = 7.48123(6) Å, b = 
8.18005(9) Å, c = 21.39110(19) Å, α = 90o, β = 90o, γ = 90o; V = 1309.07(2) 
Å3; Z = 4; ρcalcd = 1.260 Mg/m3; μ = 0.695 mm-1; Cu Kα radiation, λ = 1.54184 
Å; T = 100 K; 2Θmax = 137.5; 13898/2395 measured/independent 
reflections; Rint: 0.0372; Flack parameter/Hooft parameter 0.09(8)/0.05(3); R 
= 0.0312, wR = 0.0841; Δρmax = 0.220 eÅ−3, Δρmin = −0.220 eÅ−3. Colourless 







Formula: C21H30ClO7.5; Mr = 437.90; crystal dimensions: 0.09 x 0.07 x 0.01 mm;  
crystal system: Triclinic; space group: P1; a = 8.108(4) Å, b = 9.341(4) Å, c = 
28.660(12) Å, α = 81.739(14)o, β = 88.818(16)o, γ = 89.745(14)o; V = 2147.6(17) Å3; 
Z = 4; ρcalcd = 1.354 Mg/m3; μ = 0.220 mm-1; Mo Kα radiation, λ = 0.71075 Å; T = 100 
K; 2Θmax = 55.3; 57447/19551 measured/independent reflections; Rint: 0.1941; 
Flack parameter/Hooft parameter -0.16(9)/0.09(8); R = 0.0995, wR = 0.2401; Δρmax 







Formula: C20H28ClO7.5; Mr = 423.87; crystal dimensions: 0.20 x 0.08 x 0.01 mm;  
crystal system: Monoclinic; space group: P21; a = 8.05004(19)  Å, b = 43.4268(10)  
Å, c = 11.4031(3) Å, α = 90o, β = 90.034(2)o, γ = 90o; V = 3986.38(16)  Å3; Z = 8; ρcalcd 
= 1.413 Mg/m3; μ = 0.235 mm-1; Mo Kα radiation, λ = 0.71075 Å; T = 100 K; 2Θmax = 
55.3; 52007/18325 measured/independent reflections; Rint: 0.0382; Flack 
parameter/Hooft parameter 0.02(2)/0.011(17); R = 0.0691, wR = 0.1779; Δρmax = 
1.383 eÅ−3, Δρmin = −0.459 eÅ−3. Colourless plate crystals. CCDC deposition number 
1406891. 
 
N.B. this structure was refined as a 2-componant twin with the twin law [-1 0 0 0 -






Formula: C20H30O8; Mr = 398.44; crystal dimensions: 0.20 x 0.10 x 0.02 mm;  
crystal system: Monoclinic; space group: P21; a = 5.7210(4)  Å, b = 
10.3060(7)  Å, c = 16.4249(13) Å, α = 90o, β = 93.254(7)o, γ = 90o; V = 
966.87(12)  Å3; Z = 2; ρcalcd = 1.369 Mg/m3; μ = 0.879 mm-1; Cu Kα radiation, 
λ = 1.54184 Å; T = 100 K; 2Θmax = 134.8; 9102/3371 measured/independent 
reflections; Rint: 0.0778; Flack parameter/Hooft parameter 0.1(4)/0.3(3); R = 
0.0670, wR = 0.1803 Δρmax = 0.485 eÅ−3, Δρmin = −0.260 eÅ−3. Colourless 








In order to confirm the presence of chlorinated isolated compounds, bracken 
rhizomes (10 g, dry weight) were extracted with 100 ml of non-chlorinated organic 
solvents, methanol and ethyl acetate, and the extracts were  analysed by reverse-
phase HPLC with on-line photodiode array detection with and without electrospray 
ionisation-ion trap mass spectrometry. HPLC/ion trap mass spectrometry 
(HPLC/ESI-MSn)  analysis was performed on a Thermo Finnigan LC-MS system 
(Thermo Electron Corporation, USA) comprising a Finnigan Surveyor PDA Plus 
detector, a Finnigan LTQ linear ion trap with ESI source and a Waters C18 Nova-Pak 
column (4 μm, 3.9 mm x 100 mm). The autosampler tray temperature was 
maintained at 5°C and the column temperature at 30°C. Sample injection volume 
was typically 10μL, the detection wavelength was set to 210–400 nm and the flow 
rate was 1 ml min−1, with 100 μL min−1 going to the mass spectrometer. The mobile 
phase consisted of water:formic acid (A; 100:0.1, v/v) and MeOH:formic acid (B; 
100:0.1, v/v). The column was equilibrated with 95% solvent A, and the percentage 
of B increased linearly to 100% over 25  min. Ionisation parameters were optimised 
by infusion of chlorogenic acid standard at a constant rate into the LC flow. Mass 
spectra were acquired in negative ionisation mode with the following  interface 
and MS parameters: nitrogen sheath gas 30 arbitrary units, nitrogen auxiliary gas 
15 units, spray voltage 4 KV, capillary temperature 320°C, capillary voltage −1 V 
and tube lens offset −68 V.  MS/MS fragmentation was carried out at normalised 




Fig. SD1. Reverse phase HPLC-ESI-MS total ion current (TIC) chromatogram of methanol extract of bracken 





Fig. SD2. HPLC-ESI–MS/MS base peak chromatogram of methanol extract of bracken rhizomes in the 
negative ion mode. 
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Fig. SD3. HPLC/ESI–MS/MS total ion current (TIC) chromatogram of selected peak (relative retention time 
(RRt) of 9.15 min) of methanol extract of bracken rhizomes in the negative ion mode.  
RHMmeohMS2 #1552 RT: 9.15 AV: 1 NL: 1.80E1
F: ITMS - c ESI Full ms2 427.00@35.00 [ 115.00-2000.00]












































Fig. SD4. Further HPLC/MS/MS identification of the chlorinated compounds (11, 13 and 35) (loss of 162 
amu) in methanol extract of bracken rhizomes. Total ion current (TIC) of compounds at RRt of 18.8 min: 
(A) with 35Cl isotope; (B) with 37Cl isotope. HPLC/MS/MS spectrum showing [M-H-Glc]‾ (265 amu) in the 
negative mode at RRt of 18.8 min for (C) 35Cl-compounds and (D) 37Cl-compounds. 
RT: 15.00 - 22.00
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RHMmeohMS2 #2369 RT: 18.86 AV: 1 NL: 5.55E4
F: ITMS - c ESI Full ms2 265.00@cid35.00 [70.00-500.00]
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RHMmeohMS2 #2371 RT: 18.87 AV: 1 NL: 3.95E3
F: ITMS - c ESI Full ms2 267.00@cid35.00 [70.00-500.00]





































Fig. SD5. HPLC/MS identification of the sulfated-pterosin (9) in methanol extract of bracken rhizomes. 
HPLC/MS spectrum showing [M-H]‾ (297.14 amu) in the negative mode at RRt of 9.90 min for compound 
(9).  
RHMmeohFeba #729 RT: 9.90 AV: 1 NL: 4.62E2
F: ITMS - c ESI Full ms [150.00-500.00]



















Identification of SGLT1 and GLUT2 transporter inhibitors 
 
Routine cell culture - Human epithelial colorectal adenocarcinoma (Caco-2) cells 
were obtained from the American Type Culture Collection (ATCC) and cultured in 
Growth Medium consisting of Dulbecco’s modified Eagle's medium (containg 
Glutamax-1, 4.5g/L D-Glucose & 25mM Hepes (Invitrogen)), 10% Fetal Bovine 
Serum (Sigma), 1% Non-Essential Amino Acids (Invitrogen) & 1mM Sodium 
pyruvate (Sigma).  The cells were routinely passaged at approximately 80% 
confluence using TrypLE™ Express Stable Trypsin-Like Enzyme (Invitrogen) to 
detach the cells, and seeded at approximately 114 cells per mm2 in fresh tissue 
culture flasks.  Only cells between the passage numbers 45 and 49 were used for 
experiments. 
 
Preparation of differentiated Caco-2 cell monolayers – Corning® HTS Transwell® 
96 well permeable insert supports (Sigma) were collagen coated with 40μl of 
50μg/ml Rat Tail Collagen Type I (BD Biosciences) in 0.02M acetic acid for one hour 
at room temperature under sterile conditions.  The inserts were washed twice in 
Phosphate Buffered Saline (PBS (Invitrogen)) and the Caco-2 cells seeded into the 
inserts at 9.6x105 cell/ml (75μl per insert) in Growth Medium and 30ml of Growth 
medium added to the feeder plate below.  The cells were left to attach to the 
collagen matrix and form monolayers over 48hrs at 37oC, 5% CO2.  Both inserts and 
feeder plate were washed in PBS and the cells incubated with BD Entero-STIM™ 
Enterocyte Differentiation Medium containing MITO+™ Serum Extender solution 
(both BD Biosciences),75μl per insert & 30ml in feeder plate, for a further 48hrs at 
37oC, 5% CO2.   
 
Glucose Transport Inhibitor Cell Screening Assay – Differentiated cell monolayers 
were washed gently in Dulbecco's Phosphate Buffered Saline containing CaCl2 & 
MgCl2 (PBS(+) (Invitrogen) and the inserts transferred to a new Corning® HTS 
Transwell®-96 well receiver plate (Sigma).  The cells were incubated with fresh 
PBS(+) (75μl per insert & 225μl per well) for 60mins at 37oC, 5% CO2.  The PBS(+) 
was gently aspirated and replaced with 75μl per insert of either 5mM D-Glucose 
(Sigma) ± test active or 25mM D-Glucose ± test active in triplicate and 225μl per 
well of PBS(+) quickly added to each well.  The 5mM glucose wells and the 45mM 
glucose wells were incubated at 37oC, 5% CO2 for 15mins and 30mins, respectively.  
Details of all the actives tested can be found in Table 1. The cell inserts were 
transferred to a new receiver plate, the supernatant gently aspirated from the cells 
and replaced with 100μl of 100μM of Lucifer Yellow (Sigma) solution to confirm the 
integrity of the monolayers.  225μl of PBS(+) was added to each well and incubated 
at 37oC, 5% CO2 for 1hr.  The cell inserts were then discarded and the permeability 
of the membranes to Lucifer Yellow checked by measuring the fluorescence of the 
samples at 485nm (excitation) & 530nm (emission) on a Spectramax Gemini EM 
fluorescence microplate reader.  
 
Glucose Assay – The amount of glucose transported across the cell monolayers was 
measured using a glucose assay based on Invitrogen’s Amplex Red 
Glucose/Glucose oxidase Assay Kit.  Briefly, 50μl of each unknown sample was 
transferred to a black sided/clear bottom 96-well plate (Greiner Bio-One) to which 
100μl of reaction buffer (0.5μl 10mM Ampliflu Red, 1μl 10U/ml HRP, 1μl 100U/ml 
Glucose Oxidase and 97.5μl PBS (all Sigma)) was added.  After 10mins incubation 
at room temperature, the fluorescence of the samples were measured at 530nm 
(excitation) & 590nm (emission) on a Spectramax Gemini EM fluorescence 
microplate reader and the glucose concentration extrapolated from a standard 
curve.  
Table 1 - details of the actives tested for SGLT1 and GLUT2 inhibition activity in 
Caco-2 cells using 5mM D-glucose for 15 minutes and 25mM D-glucose for 30 
minutes, respectively.   The assigned class of transporter inhibited by each active is 
based on SGLT1 inhibitors having ≥20% inhibition of glucose transport at 5mM D-
glucose and ≤20% inhibition at 25mM D-glucose, and GLUT2 inhibitors having ≥20% 
inhibition at both 5mM & 25mM D-glucose levels. 
 
 
Table 1 shows the percentage of inhibition of each test active against the transport 
of glucose across a differentiated Caco-2 cell monolayer.  At the lower D-glucose 
concentration of 5mM, the early transport of glucose across the cell monolayer is 
predominantly through the apically expressed, high affinity, low capacity SGLT1 
glucose transporter.  At higher D-glucose concentrations, the SGLT1 transporter 
becomes saturated and consequently the majority of glucose transport across the 
monolayer is driven by the low affinity, high capacity GLUT2 transporter that is 
targeted to the apical membrane only following an initial SGLT1-dependent 
transport of glucose.  The screening cell model, detailed in the methods above, is 
designed to take advantage of these differences in the optimal conditions for each 
transporter to identify both SGLT1 and GLUT2 specific inhibitors.  While both SGLT1 
& GLUT2 on the apical membrane transport glucose into the enterocyte, GLUT2 is 
also expressed in the basolateral membrane where it is essential for the transport 
of glucose out of the cell.  Hence, GLUT2 specific inhibitors will not only block the 
Ave. S.D. Ave. S.D.
Phloridzin DMSO 34.81 2.64 8.42 1.42 SGLT1
Phloretin DMSO 83.60 0.95 76.20 3.88 GLUT2
Pterosin A DMSO 6.18 6.58 -2.93 1.93 None
Pterosin B DMSO 16.80 3.09 4.38 2.61 None
Pterosin C DMSO 4.34 6.75 -2.20 2.49 None
Pterosin A glucoside DMSO -3.41 7.81 -7.64 4.12 None
Pterosin B glucoside DMSO -1.38 5.95 -6.89 2.72 None
Pteroside Z DMSO 9.18 6.03 -4.49 6.46 None
a - All actives tested at 300uM.
b - Based on SGLT1 inhibitors having >20% inhibition at 5mM (glucose) and <20% inhibition at 
25mM, and GLUT2 having >20% inhibition at both 5mM & 25mM
Test Activea Solvent
% inhibition of glucose transport
Classb5mM Glucose 25mM Glucose
apically expressed transporters at high D-glucose concentrations (25mM), they will 
also enter the cell and block the exit of glucose from the enterocyte at low D-
glucose concentrations (5mM).  Therefore, to differentiate between inhibition of 
apical and basolateral transporters, each active was tested at both 5mM D-glucose 
for 15 minutes and 25mM D-glucose for 30minutes.  Actives were classed as SGLT1 
inhibitors if they exhibited a greater than 20% inhibition of glucose transport at 
5mM D-glucose and a corresponding less than 20% inhibition at 25mM D-glucose.  
Actives that were able to inhibit glucose transport by greater than 20% in both 
conditions were classed as GLUT2 specific inhibitors.  This approach was qualified 
through the use of the widely recognised specific inhibitors of both SGLT1 and 
















= Tight Junction = Direction of glucose transport = GLUT2 = SGLT1 = Enterocyte 
Figure 1 - Glucose Concentration Timeline During a Meal 
The glucose transport cell model, detailed in the methods above, is a novel in vitro 
cell system designed to mimic the localised changes in glucose concentration in the 
small intestine during the consumption of a carbohydrate rich meal (Figure 1) 
(Kellett & Brot-Laroche, 2005).  Before the meal, the concentration of free glucose 
in the lumen of the intestine is low (<5mM) and the apically expressed SGLT1 
transporter actively transports any available glucose into the enterocyte.  GLUT2 
transporters are also active on the basolateral membrane of the enterocyte, 
transporting glucose from the blood into the cell to maintain cellular metabolism 
if required.  During a meal, the local concentration of glucose begins to increase (5-
10mM) and is transported from the intestinal lumen by SGLT1 and subsequently 
into the systemic circulation via GLUT2.  As a consequence of this initial glucose 
transport across the enterocyte, intracellular stores of GLUT2 are mobilised and 
targeted to the apical membrane.  Shortly after the meal, very high local 
concentrations of glucose occur (25-100mM) as the carbohydrate content of the 
meal is broken down into monosaccharides by alpha-glucosidase enzymes located 
on the apical enterocyte membrane.  At these high levels of glucose, the high 
affinity, low capacity transporter SGLT1 becomes saturated and the majority of 
glucose transport across the enterocyte is due to the low affinity, high capacity 
GLUT2 transporters now present in the apical membrane.  These localised changes 
in luminal glucose concentrations are mimicked in vitro through an initial short 
incubation of differentiated Caco-2 cells with a low level of D-glucose (5mM for 
15mins) immediately followed by a sustained incubation with a high level of D-
glucose (final concentration of 25mM for 45mins).   
References: 
Kellett & Brot-Laroche (2005) Apical GLUT2: a major pathway of intestinal sugar 
absorption. Diabetes 54(10), 3056-62. 
 
 
SUPPORTING INFORMATION 1 (SI 1) 
Isolation and characterisation of thirteen pterosins and pterosides from 
bracken (Pteridium aquilinum (L.) Kuhn) rhizome 
Rizgar Hassan Mohammada, Mohammad Nur e-Alama,b , Martina Lahmanna, Ifat Parveenc, 
Graham J. Tizzardd, Simon J. Colesd, Mark Fowlere, Alex F. Drakef, Derren Heyesg, Vera 
Thossa,* 
 
a School of Chemistry, Bangor University, Bangor LL57 2UW, United Kingdom 
b Department of Pharmacognosy, College of Pharmacy, King Saud University, P.O. Box 2457, 
Riyadh 11451, Saudi Arabia. 
c IBERS, Aberystwyth University, Penglais, Aberystwyth SY23 3DA, UK 
d UK National Crystallography Service, School of Chemistry, University of Southampton, 
University Road, Southampton SO17 1BJ, United Kingdom 
e Strategic Science Group, Unilever R&D, Colworth Science Park, Bedford, MK44 1LQ, UK. 
f Biomolecular Spectroscopy Centre, Pharmaceutical Optical & Chiroptical Spectroscopy 
Facility, King's College London, The Wolfson Wing, WWB10 Hodgkin Building, Guy's 
Campus, London SE1 1UL, UK 
g Manchester Institute of Biotechnology, University of Manchester, 131 Princess St, Manchester 
M1 7DN 
*Corresponding Author vera.thoss@bangor.ac.uk  
List of Supporting Information: 
Figure S1. 1H NMR (CDCl3, 400 MHz) spectrum of compound 1. 
Figure S2. DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound 1.  
Figure S3. 1H-1H COSY NMR spectrum of compound 1. 
Figure S4. HSQC NMR spectrum of compound 1. 
Figure S5. HMBC NMR spectrum of compound 1. 
Figure S6. FT-ICR-MS spectrum of compound 1. 
Figure S7. UV spectrum of compound 1 in CH3OH. 
Figure S8. FT-IR spectrum of compound 1 in CHCl3. 
Figure S9. 1H NMR (CD3OD, 400 MHz) spectrum of compound 2. 
Figure S10. DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound 2. 
Figure S11. 1H-1H COSY NMR spectrum of compound 2. 
Figure S12. HSQC NMR spectrum of compound 2. 
Figure S13. HMBC NMR spectrum of compound 2. 
Figure S14. FT-ICR-MS spectrum of compound 2. 
Figure S15. UV spectrum of compound 2 in CH3OH. 
Figure S16. FT-IR spectrum of compound 2 in CH3OH. 
Figure S17. 1H NMR (CDCl3, 400 MHz) spectrum of compound 2 after acetylation reaction. 
Figure S18. 1H-1H COSY NMR spectrum of compound 2 after acetylation reaction. 
Figure S19. DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound 2 after acetylation reaction. 
Figure S20. 1H NMR (CDCl3, 400 MHz) spectrum of compound 3. 
Figure S21. DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound 3. 
Figure S22. 1H-1H COSY NMR spectrum of compound 3. 
Figure S23. HSQC NMR spectrum of compound 3. 
Figure S24. HMBC NMR spectrum of compound 3. 
Figure S25. FT-ICR-MS spectrum of compound 3. 
Figure S26. UV spectrum of compound 3 in CH3OH. 
Figure S27. FT-IR spectrum of compound 3 in CHCl3. 
Figure S28. 1H NMR (CD3OD, 400 MHz) spectrum of compound 4. 
Figure S29. DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound 4. 
Figure S30. 1H-1H COSY NMR spectrum of compound 4. 
Figure S31. HSQC NMR spectrum of compound 4. 
Figure S32. HMBC NMR spectrum of compound 4. 
Figure S33. FT-ICR-MS spectrum of compound 4. 
Figure S34. UV spectrum of compound 4 in CH3OH. 
Figure S35. FT-IR spectrum of compound 4 in CH3OH. 
Figure S36. 1H NMR (CDCl3, 400 MHz) spectrum of compound 5. 
Figure S37. DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound 5. 
Figure S38. 13C NMR (CDCl3, 100 MHz) spectrum of compound 5. 
Figure S39. 1H-1H COSY NMR spectrum of compound 5. 
Figure S40. HSQC NMR spectrum of compound 5. 
Figure S41. HMBC NMR spectrum of compound 5. 
Figure S42. FT-ICR-MS spectrum of compound 5. 
Figure S43. UV spectrum of compound 5 in CH3OH. 
Figure S44. FT-IR spectrum of compound 5 in CHCl3. 
Figure S45. 1H NMR (CD3OD, 400 MHz) spectrum of compound 6. 
Figure S46. DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound 6. 
Figure S47. 1H-1H COSY NMR spectrum of compound 6. 
Figure S48. HSQC NMR spectrum of compound 6. 
Figure S49. HMBC NMR spectrum of compound 6. 
Figure S50. FT-ICR-MS spectrum of compound 6. 
Figure S51. UV spectrum of compound 6 in CH3OH. 
Figure S52. FT-IR spectrum of compound 6 in CH3OH. 
Figure S53. 1H NMR (CDCl3, 400 MHz) spectrum of compound 7. 
Figure S54. DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound 7. 
Figure S55. 13C NMR (CDCl3, 100 MHz) spectrum of compound 7. 
Figure S56. 1H-1H COSY NMR spectrum of compound 7. 
Figure S57. HSQC NMR spectrum of compound 7. 
Figure S58. HMBC NMR spectrum of compound 7. 
Figure S59. FT-ICR-MS spectrum of compound 7. 
Figure S60. UV spectrum of compound 7 in CH3OH. 
Figure S61. FT-IR spectrum of compound 7 in CHCl3. 
Figure S62. 1H NMR ((CD3)2CO, 400 MHz) spectrum of compound 8. 
Figure S63. DEPTQ NMR ((CD3)2CO, 100 MHz) spectrum of compound 8. 
Figure S64. 1H-1H COSY NMR spectrum of compound 8. 
Figure S65. HSQC NMR spectrum of compound 8. 
Figure S66. HMBC NMR spectrum of compound 8. 
Figure S67. FT-ICR-MS spectrum of compound 8. 
Figure S68. UV spectrum of compound 8 in CH3OH. 
Figure S69. FT-IR spectrum of compound 8 in CH3OH. 
Figure S70. 1H NMR (CD3OD, 500 MHz) spectrum of compound 9. 
Figure S71. DEPTQ NMR (CD3OD, 125 MHz) spectrum of compound 9. 
Figure S72. HMBC NMR spectrum of compound 9. 
Figure S73. FT-ICR-MS spectrum of compound 9. 
Figure S74. UV spectrum of compound 9 in CH3OH. 
Figure S75. FT-IR spectrum of compound 9 in CH3OH. 
Figure S76. 1H NMR (CD3OD, 400 MHz) spectrum of compound 10. 
Figure S77. DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound 10. 
Figure S78. 1H-1H COSY NMR spectrum of compound 10. 
Figure S79. HSQC NMR spectrum of compound 10. 
Figure S80. HMBC NMR spectrum of compound 10. 
Figure S81. FT-ICR-MS spectrum of compound 10. 
Figure S82. UV spectrum of compound 10 in CH3OH. 
Figure S83. FT-IR spectrum of compound 10 in CH3OH. 
Figure S84. 1H NMR (CDCl3, 400 MHz) spectrum of compound 10 after acetylation reaction. 
Figure S85. 1H-1H COSY NMR spectrum of compound 10 after acetylation reaction. 
Figure S86. DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound 10 after acetylation reaction. 
Figure S87. 1H NMR (CD3OD, 400 MHz) spectrum of compound 11. 
Figure S88. DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound 11. 
Figure S89. 1H-1H COSY NMR spectrum of compound 11. 
Figure S90. HSQC NMR spectrum of compound 11. 
Figure S91. HMBC NMR spectrum of compound 11. 
Figure S92. FT-ICR-MS spectrum of compound 11. 
Figure S93. UV spectrum of compound 11 in CH3OH. 
Figure S94. FT-IR spectrum of compound 11 in CH3OH. 
Figure S95. 1H NMR (CDCl3, 400 MHz) spectrum of compound 11 after acetylation reaction. 
Figure S96. 1H-1H COSY NMR spectrum of compound 11 after acetylation reaction. 
Figure S97. DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound 11 after acetylation reaction. 
Figure S98. 1H NMR (CD3OD, 400 MHz) spectrum of compound 12. 
Figure S99. DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound 12. 
Figure S100. 1H-1H COSY NMR spectrum of compound 12. 
Figure S101. HSQC NMR spectrum of compound 12. 
Figure S102. HMBC NMR spectrum of compound 12. 
Figure S103. FT-ICR-MS spectrum of compound 12. 
Figure S104. UV spectrum of compound 12 in CH3OH. 
Figure S105. FT-IR spectrum of compound 12 in CH3OH. 
Figure S106. 1H NMR (CDCl3, 400 MHz) spectrum of compound 12 after acetylation reaction. 
Figure S107. 1H-1H COSY NMR spectrum of compound 12 after acetylation reaction. 
Figure S108. DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound 12 after acetylation reaction. 
Figure S109. 1H NMR (CD3OD, 400 MHz) spectrum of compound 13. 
Figure S110. DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound 13. 
Figure S111. 1H-1H COSY NMR spectrum of compound 13. 
Figure S112. HSQC NMR spectrum of compound 13. 
Figure S113. HMBC NMR spectrum of compound 13. 
Figure S114. FT-ICR-MS spectrum of compound 13. 
Figure S115. UV spectrum of compound 13 in CH3OH. 
Figure S116. FT-IR spectrum of compound 13 in CH3OH. 
Figure S117. 1H NMR (CDCl3, 400 MHz) spectrum of compound 13 after acetylation reaction. 
Figure S118. 1H-1H COSY NMR spectrum of compound 13 after acetylation reaction. 
Figure S119. DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound 13 after acetylation reaction. 
Figure S120. 1H-1H NOESY NMR (CD3OD, 400 MHz) spectrum of compound 13. 




































































                Figure S3. 1H-1H COSY NMR spectrum of compound 1. 
 
 






















              Figure S5. HMBC NMR spectrum of compound 1. 
 
Figure S6. FT-ICR-MS spectrum of compound 1. 
pos #2 RT: 0.03 AV: 1 NL: 1.17E6
T: FTMS + p NSI u SIM ms [236.00-256.00]
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Figure S8. FT-IR spectrum of compound 1 in CHCl3. 
 






Figure S10. DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound 2. 
 
 





              Figure S11. 1H-1H COSY NMR spectrum of compound 2. 
 
 







               Figure S13. HMBC NMR spectrum of compound 2. 
 
 
Figure S14. FT-ICR-MS spectrum of compound 2. 
pos #1 RT: 0.01 AV: 1 NL: 2.06E6
T: FTMS + p NSI u SIM ms [399.00-419.00]
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Figure S15. UV spectrum of compound 2 in CH3OH. 
 
 





















Figure S17. 1H NMR (CDCl3, 400 MHz) spectrum of compound 2 after acetylation reaction 
 





Figure S19. DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound 2 after acetylation reaction 
 
 





Figure S21. DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound 3. 
 
 




                      Figure S23. HSQC NMR spectrum of compound 3. 
 









Figure S25. FT-ICR-MS spectrum of compound 3. 
pos #3 RT: 0.04 AV: 1 NL: 6.74E5
T: FTMS + p NSI u SIM ms [235.00-255.00]
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Figure S27. FT-IR spectrum of compound 3 in CHCl3. 
 




Figure S29. DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound 4. 
 
 




            Figure S31. HSQC NMR spectrum of compound 4. 
 
 








Figure S33. FT-ICR-MS spectrum of compound 4. 
neg #2 RT: 0.03 AV: 1 NL: 7.30E5
T: FTMS - p NSI u SIM ms [235.00-255.00]
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Figure S35. FT-IR spectrum of compound 4 in CH3OH. 
 





Figure S37. DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound 5. 
 





               Figure S39. 1H-1H COSY NMR spectrum of compound 5. 
 








              Figure S41. HMBC NMR spectrum of compound 5. 
 
Figure S42. FT-ICR-MS spectrum of compound 5. 
pos #8 RT: 0.12 AV: 1 NL: 1.73E5
T: FTMS + p NSI u SIM ms [259.00-279.00]









































Figure S43. UV spectrum of compound 5 in CH3OH. 
 




Figure S45. 1H NMR (CD3OD, 400 MHz) spectrum of compound 6. 
 




                  Figure S47. 1H-1H COSY NMR spectrum of compound 6. 
 
 






      Figure S49. HMBC NMR spectrum of compound 6. 
 
 
Figure S50. FT-ICR-MS spectrum of compound 6. 
 
pos #6 RT: 0.09 AV: 1 NL: 8.50E6
T: FTMS + p NSI u SIM ms [253.00-273.00]
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Figure S51. UV spectrum of compound 6 in CH3OH. 
 
 





Figure S53. 1H NMR (CDCl3, 400 MHz) spectrum of compound 7. 
 
 






Figure S55. 13C NMR (CDCl3, 100 MHz) spectrum of compound 7. 
 
 




                Figure S57. HSQC NMR spectrum of compound 7. 
 
 


















Figure S59. FT-ICR-MS spectrum of compound 7. 
 
pos #1 RT: 0.01 AV: 1 NL: 1.21E6
T: FTMS + p NSI u SIM ms [273.00-293.00]
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Figure S61. FT-IR spectrum of compound 7 in CHCl3. 
 
 






Figure S63. DEPTQ NMR ((CD3)2CO, 100 MHz) spectrum of compound 8. 
 
 




            Figure S65. HSQC NMR spectrum of compound 8. 
 
 










Figure S67. FT-ICR-MS spectrum of compound 8. 
 
pos #1 RT: 0.01 AV: 1 NL: 8.96E6
T: FTMS + p NSI u SIM ms [257.00-277.00]
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Figure S69. FT-IR spectrum of compound 8 in CH3OH. 
 
 





Figure S71. DEPTQ NMR (CD3OD, 125 MHz) spectrum of compound 9. 
 
 










Figure S73. FT-ICR-MS spectrum of compound 9. 
 
35_neg #1 RT: 0.00 AV: 1 NL: 7.79E6
T: FTMS - c NSI Full ms [200.00-800.00]
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Figure S75. FT-IR spectrum of compound 9 in CH3OH. 
 
 





Figure S77. DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound 10. 
 
 





            Figure S79. HSQC NMR spectrum of compound 10. 
 
 








Figure S81. FT-ICR-MS spectrum of compound 10. 
 
pos #1 RT: 0.00 AV: 1 NL: 6.35E4
T: FTMS + p NSI u SIM ms [405.00-425.00]
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Figure S83. FT-IR spectrum of compound 10 in CH3OH. 
 
 







Figure S85. 1H-1H COSY NMR spectrum of compound 10 after acetylation reaction 
 
 






Figure S87. 1H NMR (CD3OD, 400 MHz) spectrum of compound 11. 
 
 





                   Figure S89. 1H-1H COSY NMR spectrum of compound 11. 
 
 








                       Figure S91. HMBC NMR spectrum of compound 11. 
 
 
Figure S92. FT-ICR-MS spectrum of compound 11. 
 
neg #1 RT: 0.00 AV: 1 NL: 1.84E4
T: FTMS - p NSI u SIM ms [417.00-437.00]

















































Figure S93. UV spectrum of compound 11 in CH3OH. 
 
 




















Figure S95. 1H NMR (CDCl3, 400 MHz) spectrum of compound 11 after acetylation reaction 
 
 






Figure S97. DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound 11 after acetylation reaction 
 







Figure S99. DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound 12. 
 
 





Figure S101. HSQC NMR spectrum of compound 12. 
 
 







Figure 103. FT-ICR-MS spectrum of compound 12. 
 
neg #3 RT: 0.04 AV: 1 NL: 8.54E4
T: FTMS - p NSI u SIM ms [403.00-423.00]
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Figure S105. FT-IR spectrum of compound 12 in CH3OH. 
 
 




















Figure S107. 1H-1H COSY NMR spectrum of compound 12 after acetylation reaction 
 
 





Figure S109. 1H NMR (CD3OD, 400 MHz) spectrum of compound 13. 
 
 




              Figure S111. 1H-1H COSY NMR spectrum of compound 13. 
 
 






Figure S113. HMBC NMR spectrum of compound 13. 
 
 
Figure S114. FT-ICR-MS spectrum of compound 13. 
 
neg #1 RT: 0.01 AV: 1 NL: 4.13E4
T: FTMS - p NSI u SIM ms [417.00-437.00]










































Figure S115. UV spectrum of compound 13 in CH3OH. 
 
 








Figure S117. 1H NMR (CDCl3, 400 MHz) spectrum of compound 13 after acetylation reaction 
 
 





Figure S119. DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound 13 after acetylation reaction 
 
Figure S120. 1H-1H NOESY NMR (CD3OD, 400 MHz) spectrum of compound 13. 
Acetylation of compounds 2 and 10-13 
Accurately 1 mg of each compound was dissolved with 100 µL of dry pyridine in a HPLC vial 
and then 50 µL of acetic anhydride was added. The vial was immersed and sonicated for 1 hour 
and left overnight. The reaction mixture was diluted with 400 µL of CDCl3 containing 
tetramethylsilane (TMS) as an internal standard. 1H NMR and COSY were recorded in the range 





















Fig. 1. Chemical structures of isolated novel and known compounds from bracken rhizomes where 
compounds 1-9 & 11-13 represent new natural products.  
 
 
Fig. 2. The absolute stereochemistry of compounds 10, 15, 17, 18, 31 and 35 obtained from 
bracken rhizomes, as established by X-ray crystallography (Figs. 5, 6 and SI2). Compound 10 







Fig. 3. Chemical structures of pterosins and pterosides 14, 27, 29 (Lee et al., 2012), 16, 30, 32 
(Kuroyanagi et al., 1979), 19-25 (Fukuoka et al., 1978) and 34 (Castillo et al., 2003) obtained from 














Fig. 6. The CD spectra of 1, 15, 23, 27, 29, and 30 in methanol illustrating the superposition of a 
longer wavelength positively signed vibronic progression and a shorter wavelength negatively 
signed vibronic progression.  The CD of 1 has been offset by -20 mdeg to indicate the overall shift 
to longer wavelength of the n →π* as the compound is tricyclic. 
 
  

































(15)                                     (17)                                      (18) 




(31)                                                         (35) 
(2R)-pteroside B                                      (2S)-pteroside K 
 








In Fig. 7, thermal ellipsoid plots of four crystal structures (cis-pterosin C, trans-pterosin C, (2S)-
pterosin A, (2R)-pteroside B and (2S)-pteroside K) with ellipsoids shown at 50% probability.  N.B. 
pteroside K crystallises as a hemihydrate with four molecules of pteroside K and two molecules 
of water in the asymmetric unit.  Only one molecule of the pteroside K structure is shown here for 
clarity.  
 
Fig. 8. Thermal ellipsoid plot of rhedynoside B (10) with ellipsoids shown at 50% probability. 
N.B. rhedynoside B crystallises as a hemihydrate with four molecules of rhedynoside B and two 
molecules of water in the asymmetric unit.  Only one molecule of the rhedynoside B structure is 








































        Table 1 
            1H NMR (400 MHz) spectral data± of compounds 1, 3 & 5 in CDCl3 and 2 & 4 in CD3OD (δ in ppm, 


























2 - - - - - 
3 3.06, 2.77 (d, J 
= 17.5) 
3.45, 2.75 (d, J = 
17.4) 
3.22 (s) 3.19, 3.10 (d, 
J = 17.0) 
3.15 (d, J 
= 2.8) 
4 6.93 (s) 7.01 (s) 8.05 (s) 7.29 (s) 7.39 (s) 
5 - - - - - 
6 - - - - - 
7 - - - - - 
8 - - - - - 
9 - - - - - 
10 1.23 (s) 1.14 (s) 1.42 (s) 1.36 (s) 1.40 (s) 
11 3.78, 3.62 
(d, J =10.8) 
4.13, 3.48 
(d, J = 9.4) 
- - - 
12 4.80 (s) 4.79 (s) - 5.40 (s) 4.84 (s) 
13 2.76 (t, J = 5.9) 2.77 (t, J = 5.9) 3.05 (t, J = 
6.0) 
3.83 (s) 3.21 (t, J 
= 8.0) 
14 4.01 (td, J = 
1.3, 5.9, 11.8) 
4.00 (t, J = 5.9) 4.55 (t, J = 
6.0) 
- 3.62 (t, J 
= 8.0) 
15 2.56 (s) 2.54 (s) 2.64 (s) 2.62 (s) 2.67 (s) 
1′  4.21 (d, J1′, 2′ = 7.8)    
2′  3.03 (dd, J2′, 3′ = 8.9)    
3′  3.29 (m)    
4′  3.24 (m)    
5′  3.20 (m)    
6′a  3.78 (dd,  J5′, 6′a  = 
1.5,  J6′a, 6′b = 12.0) 
   
6′b 
 
 3.61 (dd, J5′, 6′b  = 4.6) 
 
   
±    Assignments were confirmed by coupling constants, COSY, DEPTQ, HSQC and HMBC 
experiments. 
        Table 2  
                  1H NMR spectral data±, ‡ of compounds 6 & 9 in CD3OD, 7 in CDCl3 and 8 in (CD3)2CO (δ in 





























2 - - - 2.63 (m) 
3 4.76 
(s) 




7.11 (s) 7.13 (s) 7.16 (s) 
5 - - - - 
6 - - - - 
7 - - - - 
8 - - - - 
9 - - - - 
10 1.19 
(s) 




3.79, 3.59 (d, J = 10.7) - - 
12 2,44 
(s) 
2.53 (s) 2.55 2.46 (s) 
13 3.78 
(s) 
5.41 (dd, J = 3.5, 10.0) 5.45 (dd, J = 5.2, 8.7) 3.15 (t, J = 
8.0) 
14 - 3.98 (dd, J13, 14a = 10.2, 
J14a, 14b =11.4) 
3.65 (dd, J13, 14b = 3.7) 
3.98 (dd, J13, 14a = 8.7, 
J14a, 14b = 11.2) 
3.81 (dd, J13, 14b = 5.2) 










±     Assignments were confirmed by coupling constants, COSY, DEPTQ, HSQC and HMBC 
experiments. 
‡     1H NMR data measured at 400 MHz for compounds 6, 7 & 8, and at 500 MHz for compound 9. 
Table 3 
1H NMR (400 MHz) spectral data± of compounds 10-13 in CD3OD (δ in ppm, J in Hz). 



























2 - - 2.66 (m) - 
3 3.45, 3.08 (d, J = 
17.4) 
2.93 (s) 3.33, 2.64 (m) 4.85 (s) 
4 7.17 (s) 7.50 (s) 7.51 (s) 7.56 (s) 
5 - - - - 
6 - - - - 
7 - - - - 
8 - - - - 
9 - - - - 
10 1.44 (s) 1.17 (s) 1.25 (d, J = 7.2) 1.28 (s) 
11 - 1.17 (s) - 1.09 (s) 
12 2.45 (s) 4.78, 5.11 (d, J = 
12.4) 
4.78, 5.10 (d, J = 
12.3) 
2.49 (s) 
13 3.22 (t, J = 8.0) 3.26 (m) 3.26 (t, J = 8.0) 3.24 (t, J = 8.0) 
14 3.63 (t, J = 8.0) 3.63 (m) 3.70 (t, J = 8.0) 3.63 (t, J = 8.0) 
15 2.65 (s) 2.66 (s) 2.66 (s) 2.65 (s) 
1′ 4.42 (d, J1′, 2′ = 7.8) 4.40 (d, J = 7.7) 4.39 (d, J = 7.7) 4.58 (d, J = 7.7) 
2′ 3.16 (dd, J2′, 3′ = 
8.0) 
3.29 (m) 3.26 (m) 3.30 (m) 
3′ 3.32++ 3.31 (m) 3.31 (m) 3.36 (m) 
4′ 3.28 (dd ~ t, J3′, 4′ = 
8.9)  
3.31 (m) 3.31 (m) 3.36 (m) 
5′ 3.12 (m) 3.36 (m) 3.36 (m) 3.42 (m) 
6′a 3.70 (dd, J5′, 6′a = 
2.5, J6′a,6′b = 12.0) 
3.92 (dd, J5′, 6′a = 
2.0, J6′a, 6′b = 12.0) 
3.92 (dd, J5′, 6′a = 
1.5, J6′a, 6′b = 11.5) 
3.93 (dd, J5′, 6′a = 
1.5, J6′a, 6′b = 11.8) 
6′b 3.60 (dd, J5′, 6′b = 
5.0) 
 
3.70 (dd, J5′, 6′b = 
4.0) 
3.69 (dd, J5′, 6′b = 
3.0) 
3.75 (dd, J5′, 6′b = 
4.0) 
±   Assignments were confirmed by coupling constants, COSY, DEPTQ, HSQC and HMBC 
experiments. 
++ Signal under solvent, confirmed by HSQC experiment. 





























































































































































































































































































































































































































































































































































±    13C NMR data measured at 100 MHz for all compounds except compound 9 which measured at 125 
MHz 
+   13C NMR data were taken in CDCl3 
++  13C NMR data were taken in CD3OD 
















†    13C NMR data were taken in (CD3)2CO 
